Answers are grounded in this paper and cite their sources.
Research identifies integrin α5β1 as key receptor for vasoinhibin's impact on angiogenesis and permeability, suggesting new therapeutic pathways.
Vasoinhibin exerts potent inhibitory effects on angiogenesis and vascular permeability through a minimal three-amino acid sequence, the HGR motif. However, the nature of the vasoinhibin receptor has remained controversial. Here, we identify integrin α5β1 as the endothelial cell-surface binding molecule mediating the actions of the HGR motif. Vasoinhibin binds to α5β1 integrin through this motif, and silencing the integrin α5 subunit abolishes the vasoinhibin-mediated inhibition of endothelial cell proliferation, invasion, and permeability. Notably, the HGR motif activates integrin α5β1, as reflected by an increase in endothelial cell adhesion to fibronectin, the canonical ligand of integrin α5β1. These findings identify integrin α5β1 as the molecular target of vasoinhibin mediating its antiangiogenic and anti-vasopermeability actions. Furthermore, a novel integrin activation mechanism leading to suppressed angiogenesis is unveiled, thereby challenging the conventional integrin inhibition approach as a therapeutic intervention.
No takes yet. Share an insight, caveat, or question.
Zamora et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: